Epoprostenol

Dosage for Epoprostenol is highly individualized and involves a process called titration. There is no single "standard" dose; rather, the dose is adjusted based on the patient's clinical response and their tolerance for side effects.

• Initial Dose: The starting dose is typically 2 nanograms per kilogram of body weight per minute (ng/kg/min).
• Titration Phase: The dose is increased in increments of 1 to 2 ng/kg/min every few days or weeks. The goal is to reach the highest dose that provides the maximum benefit for the heart and lungs while keeping side effects (like headache or jaw pain) manageable.
• Maintenance Dose: Most patients eventually settle on a maintenance dose between 25 and 40 ng/kg/min, although some patients may require doses exceeding 100 ng/kg/min over several years of treatment as the disease progresses or as tolerance develops.

Epoprostenol is used in pediatric patients with severe PAH, although FDA-approved labeling for children is more limited than for adults. Pediatric dosing usually follows the same ng/kg/min weight-based protocol used in adults. Clinical studies have shown that children often require higher weight-based doses than adults to achieve similar therapeutic effects. Pediatric initiation must be performed by a pediatric cardiologist or pulmonologist experienced in PAH.

Renal Impairment

Specific dosage adjustments for renal (kidney) impairment have not been established in clinical trials. However, because Epoprostenol is rapidly hydrolyzed in the blood rather than cleared by the kidneys, major adjustments are usually not required. Clinical monitoring for fluid overload is essential.

Hepatic Impairment

Patients with hepatic (liver) impairment may have decreased clearance of the drug, potentially leading to higher blood levels. Healthcare providers usually titrate more slowly in these patients and monitor closely for dose-related side effects like hypotension (low blood pressure).

Elderly Patients

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Epoprostenol is administered via continuous intravenous infusion through a central venous catheter (a permanent tube inserted into a large vein in the chest). This catheter is connected to a small, portable infusion pump (such as a CADD pump).

1. 1Reconstitution: The medication comes as a dry powder. It must be mixed with a specific sterile diluent provided by the manufacturer.
2. 2Sterile Technique: Because the catheter goes directly to the heart, patients and caregivers must use strict sterile (aseptic) techniques when mixing the drug and changing the tubing to prevent life-threatening blood infections (sepsis).
3. 3Continuous Flow: The pump must never be turned off. Patients must carry the pump with them at all times (24/7).
4. 4Storage: Depending on the brand, the mixed solution may need to be kept cold with ice packs or may be stable at room temperature. Unmixed vials should be stored at room temperature (15°C to 25°C or 59°F to 77°F) and protected from light.

A missed dose of Epoprostenol is a medical emergency. Because the half-life is only a few minutes, stopping the infusion can cause a sudden, severe increase in pulmonary blood pressure (rebound PAH). Symptoms of a missed dose or pump failure include shortness of breath, dizziness, and chest pain. Patients are instructed to always have a backup pump, extra batteries, and a backup supply of medication ready at all times.

Signs of an overdose are generally exaggerations of the drug's vasodilatory effects. These include:

• Severe headache
• Nausea and vomiting
• Profound hypotension (low blood pressure)
• Flushing
• Rapid heart rate (tachycardia)

In the event of an overdose, the infusion rate should be reduced or temporarily stopped under medical supervision. Because the drug clears so quickly, symptoms usually resolve within minutes of stopping the infusion.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop the medication without immediate medical guidance. Any interruption in therapy can be fatal.

Most patients receiving Epoprostenol will experience side effects, particularly during the dose-titration phase. These are often referred to as "prostanoid side effects."

• Flushing: A feeling of warmth and redness in the face and neck. This is caused by the widening of blood vessels near the skin.
• Headache: Often described as a throbbing sensation, which usually lessens over time as the body adjusts to the dose.
• Jaw Pain (Mandibular Pain): A very specific side effect of prostacyclins. It often occurs with the first bite of food (first-bite syndrome).
• Nausea and Vomiting: Gastrointestinal upset is common during dose increases.
• Diarrhea: Loose stools or abdominal cramping.
• Musculoskeletal Pain: Pain in the legs, feet, or back.
• Tachycardia: An abnormally fast heart rate as the body compensates for vasodilation.

• Anxiety or Agitation: Some patients report feeling "jittery."
• Hypotension: Blood pressure may drop too low, leading to lightheadedness.
• Injection Site Pain: Pain or redness at the site where the catheter enters the skin.
• Chest Pain: While the drug treats PAH, the changes in hemodynamics can sometimes cause temporary chest discomfort.

• Thrombocytopenia: A decrease in the number of platelets in the blood, which can increase the risk of bleeding.
• Hyperthyroidism: Rare cases of overactive thyroid have been reported with long-term prostacyclin use.
• Splenomegaly: Enlargement of the spleen.

> Warning: Stop taking Epoprostenol and call your doctor immediately or seek emergency care if you experience any of these.

1. 1Sepsis (Blood Infection): Because of the long-term central venous catheter, there is a high risk of infection. Symptoms include high fever, chills, redness or pus at the catheter site, and feeling very ill. This can be fatal if not treated with IV antibiotics immediately.
2. 2Pulmonary Edema: If you develop sudden, severe shortness of breath and cannot lie flat, it may indicate that the drug is causing fluid to build up in the lungs (often a sign of underlying pulmonary veno-occlusive disease).
3. 3Rebound Pulmonary Hypertension: If the pump stops or the tubing kinks, you may experience a rapid return of PAH symptoms: extreme shortness of breath, blue lips (cyanosis), and fainting.
4. 4Severe Bleeding: Unexplained bruising, nosebleeds, or blood in the stool, which may indicate low platelet counts.

With prolonged use, some patients may develop tolerance, meaning they need higher doses to achieve the same effect. Chronic use is also associated with thin skin or easy bruising. The most significant long-term concern is the cumulative risk of catheter-related complications, including line infections and blood clots in the large veins (venous thrombosis).

While Epoprostenol does not carry a traditional "Black Box Warning" in the sense of a boxed graphic, the FDA-approved labeling contains a prominent warning regarding the risk of rebound pulmonary hypertension. The label states that even brief interruptions in the delivery of Epoprostenol can result in rapid symptomatic deterioration and death. This warning is treated with the same clinical gravity as a black box warning by healthcare providers.

Report any unusual symptoms to your healthcare provider immediately. Most side effects can be managed by adjusting the dose titration schedule or using supportive medications (like anti-diarrheals or pain relievers).

Epoprostenol is a high-alert medication. It must only be prescribed by physicians experienced in the diagnosis and treatment of Pulmonary Arterial Hypertension. Patients must be committed to the complex task of managing a central IV line and a pump.

No formal FDA black box warning exists for Epoprostenol; however, the Warning for Sudden Interruption of Therapy is the most critical safety point. The drug has an extremely short half-life (minutes). If the infusion is stopped suddenly—due to pump failure, battery death, or a displaced catheter—it can lead to a "rebound" effect where pulmonary pressures skyrocket, potentially leading to acute right-heart failure and death.

• Catheter-Related Infections: The central venous catheter is a direct portal for bacteria to enter the bloodstream. Patients must be trained in sterile dressing changes and line maintenance.
• Pulmonary Veno-Occlusive Disease (PVOD): If a patient develops pulmonary edema (fluid in the lungs) when starting Epoprostenol, they may have PVOD. In such cases, Epoprostenol should be discontinued, as it can be life-threatening.
• Bleeding Risk: Because Epoprostenol inhibits platelet clumping, it may increase the risk of bleeding, especially in patients already taking blood thinners like warfarin (Coumadin) or aspirin.
• Vasodilation Effects: Use with caution in patients with low blood pressure or those who are dehydrated, as the drug can cause significant hypotension.

Patients on Epoprostenol require frequent and rigorous monitoring:

• Hemodynamic Monitoring: Initially, right-heart catheterization is used to measure the drug's effect on lung pressure.
• Blood Counts: Periodic CBC (Complete Blood Count) to check for thrombocytopenia (low platelets).
• Thyroid Function: Baseline and periodic thyroid tests may be recommended.
• Catheter Site Inspection: Daily checks for signs of infection (redness, warmth, swelling).
• Weight: Daily weighing to check for sudden fluid retention.

Epoprostenol itself does not typically cause sedation. However, the underlying condition (PAH) can cause fainting and dizziness. Furthermore, side effects like severe headache or hypotension can impair the ability to drive. Patients should ensure they feel stable on their current dose before operating a vehicle.

Alcohol is a vasodilator (it widens blood vessels). Combining alcohol with Epoprostenol can lead to an additive effect, significantly increasing the risk of fainting, dizziness, and dangerously low blood pressure. Patients are generally advised to avoid or strictly limit alcohol consumption.

Epoprostenol must never be stopped abruptly. If the drug needs to be discontinued (for example, if a patient is transitioning to a different medication), it must be done in a hospital setting under continuous monitoring. The dose is gradually tapered down (reduced) over hours or days to allow the body to adjust.

> Important: Discuss all your medical conditions, especially any history of heart failure or bleeding disorders, with your healthcare provider before starting Epoprostenol.

There are no absolute drug-drug contraindications where Epoprostenol must never be used, but there are combinations that carry extreme risk.

• Other Potent Vasodilators in unstable patients: Using Epoprostenol with other high-dose IV vasodilators without careful titration can lead to cardiovascular collapse.

• Anticoagulants (e.g., Warfarin, Heparin): Most PAH patients are on anticoagulants to prevent clots. Epoprostenol also inhibits platelets. The combination significantly increases the risk of major bleeding. Doctors will monitor the INR and clinical signs of bleeding very closely.
• Antiplatelet Agents (e.g., Aspirin, Clopidogrel): These drugs have an additive effect with Epoprostenol on platelet function, further increasing bleeding risks.
• Antihypertensives (e.g., Beta-blockers, ACE inhibitors): Taking medications for high blood pressure along with Epoprostenol can cause blood pressure to drop too low (hypotension).
• Diuretics (Water Pills): While often used together to manage fluid, the combination can sometimes lead to dehydration and low blood pressure.

• Digoxin: Some studies suggest that starting Epoprostenol may cause a transient increase in digoxin levels. While usually not clinically significant, monitoring is advised.
• NSAIDs (e.g., Ibuprofen, Naproxen): These can increase bleeding risk and may also reduce the effectiveness of blood pressure medications.

• High-Fat Meals: There is no evidence that food affects the metabolism of IV Epoprostenol.
• Caffeine: Large amounts of caffeine can increase heart rate, which may worsen the tachycardia caused by Epoprostenol.
• Grapefruit: Unlike many oral drugs, IV Epoprostenol is not metabolized by the CYP3A4 enzyme, so grapefruit juice does not typically interfere with its levels.

• Ginkgo Biloba, Garlic, Ginger, and Ginseng: These supplements have natural antiplatelet properties. Taking them with Epoprostenol can further increase the risk of bruising and bleeding.
• St. John's Wort: While it affects many drugs via the liver, it has a minimal direct impact on Epoprostenol levels, though it may interact with other PAH medications.

Epoprostenol does not typically interfere with standard laboratory tests, though its effect on platelets will be reflected in platelet aggregation studies.

Management Strategy:

1. 1Mechanism: Most interactions are pharmacodynamic (the drugs have additive effects on the body) rather than pharmacokinetic (the drugs change each other's blood levels).
2. 2Consequence: The primary risks are excessive bleeding or excessively low blood pressure.
3. 3Strategy: Frequent monitoring of vital signs and laboratory parameters during any change in medication regimen.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter pain relievers.

Epoprostenol must NEVER be used in the following circumstances:

1. 1Congestive Heart Failure due to Severe Left Ventricular Systolic Dysfunction: Epoprostenol is indicated for pulmonary hypertension (right-sided heart issue). In patients with left-sided heart failure (where the left ventricle cannot pump blood out to the body effectively), Epoprostenol can cause a dangerous buildup of fluid in the lungs and worsen heart failure. This is because the drug increases the amount of blood returning to the left side of the heart, which the weakened left ventricle cannot handle.
2. 2Known Hypersensitivity: Patients with a known severe allergy to Epoprostenol or any of the ingredients in the diluent (such as glycine) must not use the drug.
3. 3Pulmonary Veno-Occlusive Disease (PVOD): While not an absolute contraindication for starting, it becomes an absolute contraindication for continuing if the patient develops pulmonary edema during the initial dose titration.

These are conditions where the doctor must weigh the benefits against significant risks:

• Active Bleeding: Because the drug prevents platelets from clumping, it can worsen an active stomach ulcer or intracranial hemorrhage.
• Severe Hepatic Impairment: Due to the potential for reduced clearance and increased side effects.
• Pregnancy: While not contraindicated, it is used only when the benefit to the mother clearly outweighs the risk to the fetus.

Patients who have had allergic reactions to other prostanoids (such as Treprostinil or Iloprost) should be monitored very closely, although cross-sensitivity is not guaranteed as the chemical structures differ.

> Important: Your healthcare provider will evaluate your complete medical history, including an echocardiogram to check your left-heart function, before prescribing Epoprostenol.

Epoprostenol is classified as Pregnancy Category B (in older FDA systems). Animal studies have not shown evidence of fetal harm. In humans, data is limited but generally positive. PAH itself carries a very high risk of maternal mortality (up to 30-50%). Therefore, clinical guidelines generally recommend continuing Epoprostenol during pregnancy if it is necessary to maintain the mother's stability. It is not known to be teratogenic (causing birth defects), but delivery must be carefully planned in a high-risk obstetric center.

It is not known whether Epoprostenol is excreted in human milk. Because many drugs are excreted in milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Safety and effectiveness in pediatric patients have been established through clinical experience and small studies. Children with PAH often have a more aggressive disease course. Epoprostenol is often used in children who are failing oral therapies. Special care must be taken regarding the child's ability to manage the pump and the risk of accidental disconnection during play or school.

Clinical studies of Epoprostenol did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, starting at the low end of the dosing range. There is a higher risk of falls in elderly patients, which can be dangerous if the IV line is pulled out.

No specific studies have been performed in patients with renal impairment. However, since the drug is primarily broken down in the blood, it is generally considered safe for use in patients with kidney disease, including those on dialysis. Careful monitoring of fluid balance is required, as the IV diluent adds to the patient's daily fluid intake.

Epoprostenol should be used with caution in patients with hepatic impairment. These patients may be more sensitive to the vasodilatory effects of the drug. Slower titration is recommended for patients with Child-Pugh Class B or C liver disease.

> Important: Special populations require individualized medical assessment and frequent follow-up with a PAH specialist.

Epoprostenol is a synthetic version of the naturally occurring prostaglandin, Prostacyclin (PGI2). Its primary molecular target is the IP receptor, a G-protein-coupled receptor found on the surface of vascular smooth muscle cells and platelets.

Upon binding to the IP receptor, Epoprostenol stimulates the enzyme adenylate cyclase. This enzyme converts adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP). The increase in intracellular cAMP leads to the phosphorylation of various proteins that ultimately cause a decrease in intracellular calcium. Lower calcium levels in the smooth muscle cells of the pulmonary arteries lead to relaxation (vasodilation). In platelets, the increase in cAMP prevents the activation and clumping (aggregation) of the cells.

• Onset of Action: Immediate upon starting the IV infusion.
• Duration of Effect: Extremely short. Effects begin to dissipate within 2 to 6 minutes of stopping the infusion.
• Tolerance: Some patients develop tachyphylaxis (a rapid decrease in response to the drug) over months or years, requiring higher doses to maintain the same pulmonary artery pressure.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (Intravenous) |

| Protein Binding | Not extensively bound |

| Half-life | 2 to 6 minutes |

| Tmax | Immediate (IV) |

| Metabolism | Spontaneous hydrolysis; enzymatic degradation |

| Excretion | Renal (82% as metabolites), Fecal (4%) |

• Molecular Formula: C20H31NaO5 (as sodium salt)
• Molecular Weight: 374.4 g/mol
• Solubility: Highly soluble in water and the provided alkaline diluent.
• Chemical Structure: It is a prostanoid consisting of a five-membered ring and two side chains. It is highly unstable at low pH.

Epoprostenol is the founding member of the Prostacyclin Analog class. Related medications include Treprostinil (Remodulin), which has a longer half-life, and Iloprost (Ventavis), which is inhaled. It is also related to the oral IP receptor agonist Selexipag (Uptravi).